Molecular imaging used to differentiate cerebral amyloid angiopathy and Alzheimer’s disease


  • [18F]FDG positron emission tomography (PET)/computed tomography (CT) may have diagnostic utility in differentiating cerebral amyloid angiopathy (CAA) in general and preclinical Alzheimer’s disease (AD), in particular in patients with positive amyloid PET.

Why this matters

  • CAA is increasingly encountered in daily neurological routine, but a definite CAA diagnosis requires a full post-mortem analysis.

  • A similar recent study was conducted using early-phase 11C-labelled Pittsburgh compound B PET to distinguish probable CAA and AD, based on known histopathological and imaging topographic differences between these two disorders.

  • However, amyloid PET is not widely available, so this study sought a more clinically available alternative.